(Total Views: 380)
Posted On: 05/13/2025 12:11:20 PM
Post# of 153064
Oncology – March 2025 Update
The Company continues to prioritize oncology in 2025, as we believe this indication holds the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval.
The Company continues to prioritize oncology in 2025, as we believe this indication holds the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval.
(3)
(0)Scroll down for more posts ▼
